ClinicalTrials.gg
CompletedNCT06778850Updated Sep 18, 2026

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

A Phase 1/2 interventional study of MDR-001 and palcebo in Overweight and Obese Volunteers, sponsored by MindRank AI Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by MindRank AI Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Jun 2023, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Overweight with a site in China — 123 open to participants now, 166 under way, 43 of them phase 3. Overweight · China.

Enrollment
134th of 296
128 · median 120
Started
2023
with 32 others
Phase 1/2
6 of 330
2 open now
Registered
142nd of 330
by date

Among the 330 studies in Overweight with a site in China, this one is the 134th largest by enrollment of the 296 interventional ones that give a count, is one of 33 that started in 2023, is one of 6 in phase 1/2, and was the 142nd registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

123 of the 330 studies in Overweight with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Overweight with a site in China, or all of them as a file.
02

Study summary

To investigate the safety and tolerability after single and multiple ascending doses of MDR-001 Tablets administered orally in healthy participants and obese/ overweight participants.

03

Conditions studied

  • Overweight and Obese Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main inclusion criteria:

  • Participants who are aged ≥ 18 and ≤ 55 years at the time of signing the , no gender restriction.
  • Participants with body weight ≥ 50 kg for males, and ≥ 45 kg for females; 18 ≤ (BMI) \< 25 kg/m2 for healthy participants, and 25 ≤ BMI ≤ 35 kg/m2 for obese/overweight participants.
  • For healthy participants, physical examination and vital signs must be normal, or abnormal but clinically insignificant. For obese/overweight participants, physical examination and vital signs must be normal, or abnormal but clinically insignificant, and the vital signs should be within following ranges: systolic blood pressure: 90-150 mmHg; diastolic blood pressure: 50-95 mmHg.

Main exclusion criteria:

  • Participants with any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers.
  • Participants with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia 2 (MEN2), or those with hereditary diseases that easily induce to medullary thyroid carcinoma.
  • Participants with a history of pancreatitis or symptomatic gallbladder disease.
  • Participants with serum calcitonin levels above the (ULN) at screening.
  • Participants with significant changes in diet or exercise habits within 3 months prior to screening.
  • Participants with abnormality; or ECG values > 450 ms for males or > 470 ms for females.
  • Participants with clinically significant abnormalities in laboratory examinations (obese/overweight participants with triglycerides ≤ 5.7 mmol/L, total cholesterol ≤ 7.75 mmol/L, low-density lipoprotein cholesterol ≤ 4.9 mmol/L, and fasting blood glucose ≤ 7 mmol/L can be included); or those with clinically significant findings indicating the following diseases within 12 months prior to screening, including but not limited to disorders of respiratory system, circulatory system, digestive system, endocrine system, rheumatological/immune system, nervous system, and blood system, and mental/psychological disorders, which are considered by the investigator as inappropriate for participation in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    MDR-001(SAD)

    Single doses of MDR-001 administered orally.

    Drug: MDR-001

  • Experimental
    Placebo (SAD)

    Placebo administered orally.

    Drug: palcebo

  • Experimental
    MDR-001 (MAD)

    Multiple doses of MDR-001 administered orally.

    Drug: MDR-001

  • Experimental
    Placebo (MAD)

    Placebo administered orally.

    Drug: palcebo

Interventions

  • Oral administration of small molecule MDR-001 tablets

  • Drugpalcebo

    Administered orally placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Day 84

Secondary outcomes

  1. PK: Area Under the Concentration Versus Time Curve (AUC) of MDR-001

    PK: AUC of MDR-001

    Time frame: Baseline through Day 84

  2. Change from Baseline in Fasting Glucose

    Change from Baseline in Fasting Glucose

    Time frame: Baseline through Day 84

  3. Pharmacokinetics (PK): Maximum Concentration (Cmax) of MDR-001

    PK: Cmax of MDR-001

    Time frame: Baseline through Day 84

  4. Change from Baseline in Glycated Hemoglobin (HbA1c)

    Change from Baseline in HbA1c

    Time frame: Baseline through Day 84

  5. Change from Baseline in Body Weight

    Change from Baseline in Body Weight

    Time frame: Baseline through Day 84

07

Study locations

1 site
  • The first hospital of Jilin University
    Changchun, Jilin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jul 2024, 13 months.

Of 24 phase 1/2 interventional studies under Overweight, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 34. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 16, 2025
StartActual
Jun 9, 2023
Primary completionActual
Jul 15, 2024
CompletionActual
Sep 30, 2024
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06778850
Lead sponsor
MindRank AI Ltd
Responsible party
Sponsor
First posted
Jan 16, 2025
Start date
Jun 9, 2023
Primary completion
Jul 15, 2024
Completion
Sep 30, 2024
Last update
Sep 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MDR-001

Start the discussion